Opt‐in for secondary findings as part of diagnostic whole‐exome sequencing: Real‐life experience from an international diagnostic laboratory

BACKGROUND: Discussion about the risks and benefits of offering secondary findings as part of genome‐wide diagnostics lacks real‐life data. We studied the opt‐in decisions of patients/families referred to whole exome study (WES) in Blueprint Genetics (BpG), a genetic testing company with customers i...

Descripción completa

Detalles Bibliográficos
Autores principales: Brunfeldt, Minna, Kaare, Milja, Saarinen, Inka, Koskenvuo, Juha, Kääriäinen, Helena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422066/
https://www.ncbi.nlm.nih.gov/pubmed/37025058
http://dx.doi.org/10.1002/mgg3.2180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10422066/
https://www.ncbi.nlm.nih.gov/pubmed/37025058
http://dx.doi.org/10.1002/mgg3.2180

Ejemplares similares